Guardant Health (NASDAQ:GH) Price Target Raised to $145.00

Guardant Health (NASDAQ:GH) had its price target lifted by BTIG Research from $140.00 to $145.00 in a report published on Friday, Marketbeat.com reports. BTIG Research currently has a buy rating on the stock.

Several other research firms have also issued reports on GH. JPMorgan Chase & Co. increased their target price on shares of Guardant Health from $90.00 to $120.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Barclays reissued an “overweight” rating and issued a $130.00 price objective on shares of Guardant Health in a report on Friday. Stifel Nicolaus boosted their price objective on Guardant Health from $100.00 to $120.00 and gave the company a “buy” rating in a research report on Friday, January 9th. Guggenheim upped their target price on Guardant Health from $115.00 to $135.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Finally, Citigroup increased their target price on Guardant Health from $135.00 to $150.00 and gave the company a “buy” rating in a research report on Friday. Twenty-one investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Guardant Health currently has an average rating of “Moderate Buy” and an average price target of $117.43.

Guardant Health Trading Down 3.1%

Guardant Health stock opened at $103.10 on Friday. The firm has a market cap of $13.52 billion, a PE ratio of -31.15 and a beta of 1.63. Guardant Health has a 12 month low of $34.88 and a 12 month high of $120.74. The stock’s 50 day simple moving average is $106.69 and its two-hundred day simple moving average is $86.51.

Guardant Health (NASDAQ:GH) last posted its earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The company had revenue of $281.27 million for the quarter, compared to analysts’ expectations of $269.74 million. Guardant Health’s revenue for the quarter was up 39.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.62) EPS. On average, equities research analysts forecast that Guardant Health will post -2.9 EPS for the current year.

Insider Buying and Selling at Guardant Health

In related news, insider Terilyn J. Monroe sold 8,571 shares of Guardant Health stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $114.09, for a total transaction of $977,865.39. Following the transaction, the insider owned 20,990 shares in the company, valued at approximately $2,394,749.10. This trade represents a 28.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Medina Manuel Hidalgo sold 1,250 shares of the business’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $105.00, for a total value of $131,250.00. Following the transaction, the director directly owned 797 shares in the company, valued at $83,685. This trade represents a 61.06% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 434,511 shares of company stock valued at $45,580,887. 6.10% of the stock is owned by company insiders.

Institutional Trading of Guardant Health

Several institutional investors and hedge funds have recently bought and sold shares of the stock. V Square Quantitative Management LLC purchased a new position in shares of Guardant Health during the fourth quarter worth $27,000. Chesapeake Asset Management LLC acquired a new position in Guardant Health during the 4th quarter worth $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in Guardant Health during the 4th quarter worth about $31,000. Elyxium Wealth LLC acquired a new stake in Guardant Health in the 4th quarter valued at about $35,000. Finally, Parallel Advisors LLC raised its position in Guardant Health by 164.7% in the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after purchasing an additional 219 shares in the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

More Guardant Health News

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Multiple brokerages raised price targets and maintained buy/overweight ratings (Leerink to $180, JPMorgan to $130, Wells Fargo to $125, BTIG to $145, Canaccord to $135), signaling analyst confidence in upside from current levels. Analyst Raises Coverage
• Positive Sentiment: Q4 revenue beat and strong growth: Guardant reported $281.3M in Q4 revenue, +39% YoY and above consensus; management issued FY2026 revenue guidance around $1.3B, above Street expectations — a growth signal for core oncology testing. Press Release
• Positive Sentiment: Research coverage expansion: Robert W. Baird initiated coverage, which can broaden institutional interest and trading liquidity. Coverage Start
• Neutral Sentiment: Conference call and transcript available — provides detail on cadence of test volume, reimbursement progress and product roadmap; useful for digging into guidance assumptions. Earnings Transcript
• Neutral Sentiment: Market materials (slide deck, press release) posted for investors to verify segment trends and margin assumptions. Slide Deck / Press Release
• Neutral Sentiment: Short-interest data flagged a “significant increase” entry but shows 0 shares / NaN in the feed — the published data appears inconsistent, so short-interest impact is unclear. Short Interest Note
• Negative Sentiment: EPS miss: GAAP loss of ($0.50) vs. consensus (~($0.43)), which disappointed some investors despite revenue upside and may have pressured the stock near the close. Earnings Reaction
• Negative Sentiment: Management left EPS guidance effectively blank in the release (revenue guidance given but no numeric EPS target), which can create uncertainty around near-term profitability expectations. Guidance Details

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.